Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

This study is a single-arm early exploratory clinical study. designed to evaluate the safety and tolerability of GT201 in combination with a PD-1 inhibitor for the treatment of advanced head and neck tumor subjects with safety and tolerability, as well as pharmacokinetic characterization and efficacy The study consists of two phases. The study consists of two phases, a dose-escalation phase and a dose-expansion phase.

Trial Details

NCT ID
NCT06190275
Phase
NA
Sponsor
Grit Biotechnology
Status
RECRUITING
Cancer Type
Squamous Cell Head and Neck Cancer
Interventions
  • GT201 in combination with PD-1 inhibitors
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • 1\. Voluntarily join the study, signed informed consent form,, willing and able to comply with the study protocol;
  • 2\. Age 18 to 70 years old;
  • 3\. Diagnosis with recurrent or metastatic head and neck malignant tumors and received≤2 lines of systemic therapy;
  • 4\. Have at least one measurable lesion that is untreated with radiotherapy or other local therapies, is accessible for tumor tissue collection (as…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Head and Neck Cancer Trials on Trialify →